An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
Psyched Wellness Ltd. to Commence Trading on the CSE on October 22, 2020
The latest psychedelic drug company to commence public trading is Psyched Wellness.
TSI EDITOR |
2020-10-21
Mind Cure’s New Medtech Platform Is A Critical Puzzle-Piece
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
TSI EDITOR |
2020-10-21
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
TSI EDITOR |
2020-10-21
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
TSI EDITOR |
2020-10-20
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
TSI EDITOR |
10/20/2020
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now